Paying users zone. Data is hidden behind hidden.

  • Get 1-month access to Regeneron Pharmaceuticals Inc. for $13.99, or

  • get full access to the entire website for at least 3 months from $49.99.

We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Apple Pay Google Pay
Verified by Visa MasterCard SecureCode American Express SafeKey
Unlock

This is a one-time payment. There is no automatic renewal.

Microsoft Excel LibreOffice Calc

Regeneron Pharmaceuticals Inc. (REGN)

Statement of Comprehensive Income

Beginner level

Comprehensive income is the change in equity (net assets) of a business enterprise during a period from transactions and other events and circumstances from non-owners sources. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners.

Regeneron Pharmaceuticals Inc., consolidated statement of comprehensive income

US$ in thousands

Microsoft Excel LibreOffice Calc
12 months ended Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014
Net income hidden hidden hidden hidden hidden
Unrealized gain (loss) on marketable securities hidden hidden hidden hidden hidden
Unrealized gain (loss) on cash flow hedges hidden hidden hidden hidden hidden
Other comprehensive income (loss), net of tax hidden hidden hidden hidden hidden
Comprehensive income hidden hidden hidden hidden hidden

Based on: 10-K (filing date: 2019-02-07), 10-K (filing date: 2018-02-08), 10-K (filing date: 2017-02-09), 10-K (filing date: 2016-02-11), 10-K (filing date: 2015-02-12).

Comprehensive income item Description The company
Net income The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Regeneron Pharmaceuticals Inc.’s net income increased from 2016 to 2017 and from 2017 to 2018.
Comprehensive income Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. Regeneron Pharmaceuticals Inc.’s comprehensive income increased from 2016 to 2017 and from 2017 to 2018.